Latest Breaking News On - Primary hyperoxaluria type - Page 2 : comparemela.com

CAGR of 7.7% | Global Fuchs Endothelial Corneal Dystrophy

The Global Fuchs Endothelial Corneal Dystrophy Market Size was valued at USD 170 Billion in 2022 and the Worldwide Fuchs Endothelial Corneal Dystrophy.

NKF Roundup: Latest Data on Tolvaptan, Terlipressin, and Lumasiran

More research from the National Kidney Foundation Spring Clinical Meeting

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

Precision BioSciences (DTIL) Reports Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities